Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Pelabresib by MorphoSys for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval
Pelabresib is under clinical development by MorphoSys and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Novartis's Pelabresib?
Pelabresib is a small molecule commercialized by Novartis, with a leading Phase III program in Myelofibrosis. According to Globaldata, it...